Management of breakthrough bleeding in extended hormonal contraceptive regimens

Details for Australian Patent Application No. 2011226911 (hide)

Owner Bayer Schering Pharma Aktiengesellschaft

Inventors Sachse, Andreas

Agent Davies Collison Cave

Pub. Number AU-A-2011226911

Parent 2005237255

Filing date 27 September 2011

Wipo publication date 20 October 2011

International Classifications

A61K 31/565 (2006.01) - not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol

A61K 31/567 (2006.01) - substituted in position 17 alpha, e.g. mestranol, norethandrolone

A61K 31/57 (2006.01) - substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone

A61K 31/575 (2006.01) - substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol

A61K 31/585 (2006.01)

A61P 15/18 (2006.01) Drugs for genital or sexual disorders

Event Publications

13 October 2011 Complete Application Filed

20 October 2011 Application Open to Public Inspection

  Published as AU-A-2011226911

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011226912-Hospital bed

2011226910-Hair styling apparatus and assembly